$-0.58 EPS Expected for Kala Pharmaceuticals, Inc. (KALA)

October 13, 2018 - By Darrin Black

Analysts expect Kala Pharmaceuticals, Inc. (NASDAQ:KALA) to report $-0.58 EPS on November, 6.They anticipate $0.02 EPS change or 3.57 % from last quarter’s $-0.56 EPS. After having $-0.60 EPS previously, Kala Pharmaceuticals, Inc.’s analysts see -3.33 % EPS growth. The stock increased 6.20% or $0.5 during the last trading session, reaching $8.56. About 874,686 shares traded or 157.35% up from the average. Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has declined 58.41% since October 14, 2017 and is downtrending. It has underperformed by 74.03% the S&P500.

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle Mucus Penetrating Particles technology. The company has market cap of $274.83 million. The company??s product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It currently has negative earnings. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases.

More notable recent Kala Pharmaceuticals, Inc. (NASDAQ:KALA) news were published by: Streetinsider.com which released: “Pre-Open Movers 10/03: (ELGX) (JCP) (TPX) Higher; (DTEA) (CENX) (KALA) Lower (more…)” on October 03, 2018, also Businesswire.com with their article: “Kala Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares” published on October 11, 2018, Seekingalpha.com published: “Kala Pharma +8.7% as shareholder discloses $20M purchase” on October 05, 2018. More interesting news about Kala Pharmaceuticals, Inc. (NASDAQ:KALA) were released by: Nasdaq.com and their article: “Here’s Why Kala Pharmaceuticals Fell as Much as 17.7% Today” published on October 03, 2018 as well as Nasdaq.com‘s news article titled: “Mid-Day Market Update: Dow Up 130 Points; Kala Pharmaceuticals Shares Slide” with publication date: October 03, 2018.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News